Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion InjuryPodsawee Mongkolpathumrat(Naresuan University), Sarawut Kumphune(Chiang Mai University)BiomedicinesApril 13, 202110.3390/biomedicines9040422Cited by 14SaveCiteExport RISWatch citationsRelated PapersCardiac endothelial ischemia/reperfusion injury-derived protein damage-associated molecular patterns disrupt the integrity of the endothelial barrier|Heliyon|2024|11Bioactive secretory leukocyte protease inhibitor (SLPI)-derived short peptides (SDSPs) attenuate LPS-induced inflammatory responses in macrophages|Scientific Reports|2026|0